Erectile Dysfunction Drugs Market by Drug Types (Major Brands) – Cialis (Tadalafil), Helleva (Lodenafil Carbonate), Levitra/Staxyn (Vardenafil), MUSE (Medicated Urethral System For Erection), Mvix (Mirodenafil), Stendra/Spedra (Avanafil), Viagra (Sildenafil Citrate), Zydena (Udenafil) and Clinical Pipeline Analysis of Phase 1, 2 and 3 Drugs – Uprima (Apomorphine), Vitaros (Alprostadil) and Forecast 2017-2021

Erectile Dysfunction Drugs Market by Drug Types (Major Brands) – Cialis (Tadalafil), Helleva (Lodenafil Carbonate), Levitra/Staxyn (Vardenafil), MUSE (Medicated Urethral System For Erection), Mvix (Mirodenafil), Stendra/Spedra (Avanafil), Viagra (Sildenafil Citrate), Zydena (Udenafil) and Clinical Pipeline Analysis of Phase 1, 2 and 3 Drugs – Uprima (Apomorphine), Vitaros (Alprostadil) and Forecast 2017-2021

Diseases, nutritional status, trauma, surgical procedures, or medications can affect erectile function by altering the nervous, vascular, or hormonal systems. The major types of erectile dysfunction include psychological erectile dysfunction, priapism characterized by painful erection in the absence of sexual stimulation, and Peyronie’s disease. Phosphodiesterase-5 (PDE-5) inhibitors are one of the most widely used and effective types of medication for treating erectile dysfunction. The first line of treatment for ED comprises oral medication of PDE 5 inhibitors, namely, sildenafil citrate, tadalafil, vardenafil, udenafil and others. Aging is considered as the major factor responsible for impeding the normal function of erection, while other factors include cardiovascular diseases, diabetes mellitus, spinal cord injuries, hypertension, and medications.

The global erectile dysfunction (ED) drugs market report estimates the market size (Revenue US$ million – 2014 to 2021) for key market segments based on the drug type by major brands such as Cialis (tadalafil), Helleva (lodenafil carbonate), Levitra/Staxyn (vardenafil), MUSE (Medicated Urethral System for Erection), Mvix (mirodenafil), Stendra/Spedra (avanafil), Viagra (sildenafil citrate), Zydena (udenafil), etc. and clinical pipeline analysis of phase 1, 2 and 3 drugs such as Uprima (apomorphine), Vitaros (alprostadil), and forecasts growth trends (CAGR% – 2017 to 2021).

The global erectile dysfunction drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global erectile dysfunction drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global erectile dysfunction drugs market and included in this report are Pfizer, Inc., Eli Lilly and Co., Bayer AG, Dong-A Pharmaceutical Co. Ltd., and Vivus, Inc.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue US$ Million, 2014-2021)
    • Forecast Estimation (Revenue US$ Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Erectile Dysfunction Drugs Market

1. Brand Type
1.1. Cialis (Tadalafil)
1.2. Helleva (Lodenafil Carbonate)
1.3. Levitra/Staxyn (Vardenafil)
1.4. MUSE (Medicated Urethral System for Erection)
1.5. Mvix (Mirodenafil)
1.6. Stendra/Spedra (Avanafil)
1.7. Viagra (Sildenafil Citrate)
1.8. Zydena (Udenafil)

2. Pipeline Analysis
2.1. Uprima (Apomorphine)
2.2. Vitaros (Alprostadil)
2.3. Others (Topiglan, Melanocortin Activators, Gene Therapy)

3. Company Profiles
3.1. Apricus Biosciences, Inc.
3.2. Bayer AG
3.3. Cristalia Produtos Quimicos Farmaceuticos Ltda.
3.4. Dong-A Pharmaceutical Co. Ltd.
3.5. Eli Lilly and Company
3.6. Meda Pharmaceuticals, Inc.
3.7. Pfizer, Inc.
3.8. S.K. Chemicals Co. Ltd.
3.9. Vivus, Inc.

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*